Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.
US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.
Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May
Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.
More information can be found in the media release.
211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests